摘要
药物负荷MPI是检测心肌异常血流灌注的重要手段。作为目前仅有的被美国FDA批准的选择性腺苷A2A受体激动剂，新的心肌负荷药物regadenoson日渐广泛地被应用于临床负荷MPI。笔者对regadenoson的基本药理机制、临床应用研究进展，尤其其作为负荷药物的诊断效能、预后价值及不良反应进行概述。
Vasodilator stress MPI plays an important role in the detection of abnormal myocardial perfusion. Currently as the only selective A2A adenosine receptor agonist approved by FDA, the new myocardial stress agent regadenoson has been increasingly used in vasodilator stress MPI on clinic. This review describes the pharmacologic properties and overviews the clinical data on regadenoson, especially its diagnostic efficacy, prognosis predicting value and adverse effect as a vasodilator stress agent.
出处
《中华核医学与分子影像杂志》
北大核心
2017年第12期815-818,共4页
Chinese Journal of Nuclear Medicine and Molecular Imaging
